Tremelimumab

IMFINZI and tremelimumab With Chemotherapy Demonstrated Overall Survival Benefit in POSEIDON Trial for 1st-line Stage IV Non-small Cell Lung Cancer

Retrieved on:

Friday, May 7, 2021

Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Clinical medicine, Health, Cancer, Lung cancer, Breakthrough therapy, Orphan drugs, Monoclonal antibodies, Cancer treatments, Durvalumab, Tremelimumab, Non-small-cell lung carcinoma, Small-cell carcinoma

b"POSEIDON was a Phase III trial of AstraZeneca\xe2\x80\x99s IMFINZI\xc2\xae (durvalumab) plus platinum-based chemotherapy or IMFINZI, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).\nPositive high-level results from the final analysis of POSEIDON showed the combination of IMFINZI, tremelimumab and chemotherapy demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone.

Key Points:

b"POSEIDON was a Phase III trial of AstraZeneca\xe2\x80\x99s IMFINZI\xc2\xae (durvalumab) plus platinum-based chemotherapy or IMFINZI, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).\nPositive high-level results from the final analysis of POSEIDON showed the combination of IMFINZI, tremelimumab and chemotherapy demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone.
This immunotherapy combination also demonstrated a statistically significant improvement in progression-free survival (PFS) versus chemotherapy alone, as previously reported in October 2019 .
As both PFS endpoints were met for IMFINZI plus chemotherapy and IMFINZI, tremelimumab and chemotherapy, the prespecified statistical analysis plan allowed for independent OS testing for the IMFINZI plus tremelimumab and chemotherapy arm.
Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.

Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics

Retrieved on:

Monday, January 11, 2021

Medical specialties, Branches of biology, Medicine, Immune system, Immunology, Immunoglobulin E, Immune response, T cell, AstraZeneca, Antigen, Cancer immunotherapy, Tremelimumab

This mapping data may inform signatures of immune response (or resistance) to cancer therapies which may provide information to guide treatment decisions.

Key Points:

This mapping data may inform signatures of immune response (or resistance) to cancer therapies which may provide information to guide treatment decisions.
We continue to demonstrate that specific T-cell immune receptor data can be utilized to inform the diagnosis and treatment for most diseases, said Sharon Benzeno, Chief Business Development Officer, Adaptive Biotechnologies.
We are thrilled to partner with AstraZeneca to realize the value of antigen-specific T-cell response data across their portfolio of transformative cancer medicines.
Adaptive will receive from AstraZeneca quarterly payments plus sequencing and data mapping fees.

IMFINZI® (durvalumab) Showed a Sustained Overall Survival Benefit in 1st-Line Extensive-Stage Small Cell Lung Cancer in the Phase III CASPIAN Trial

Retrieved on:

Friday, May 29, 2020

Monitor patients for signs and symptoms of hepatitis during and after discontinuation of IMFINZI, including clinical chemistry monitoring.

Key Points:

Monitor patients for signs and symptoms of hepatitis during and after discontinuation of IMFINZI, including clinical chemistry monitoring.
Withhold IMFINZI for Grade 2 colitis or diarrhea; permanently discontinue for Grade 3 or 4 colitis or diarrhea.
CASPIAN is a randomized, open-label, multi-center, global, Phase III trial in the 1st-line treatment of 805 patients with ES-SCLC.
Tremelimumab is being tested in a clinical trial program in combination with IMFINZI in NSCLC, bladder cancer, head and neck cancer and liver cancer cancers.

IMFINZI plus tremelimumab Demonstrated Promising Clinical Activity and Tolerability in Patients With Advanced Liver Cancer

Retrieved on:

Friday, May 29, 2020

In clinical studies enrolling 1889 patients with various cancers who received IMFINZI, hypothyroidism occurred in 11% of patients, while hyperthyroidism occurred in 7% of patients.

Key Points:

In clinical studies enrolling 1889 patients with various cancers who received IMFINZI, hypothyroidism occurred in 11% of patients, while hyperthyroidism occurred in 7% of patients.
In clinical studies enrolling 1889 patients with various cancers who received IMFINZI, type 1 diabetes mellitus occurred in
Parts two and three are evaluating IMFINZI monotherapy, tremelimumab monotherapy, and tremelimumab plus IMFINZI combination therapy, and part four evaluates bevacizumab plus IMFINZI combination therapy.
Tremelimumab is being tested in a clinical trial programme in combination with IMFINZI (durvalumab) in NSCLC, SCLC, bladder cancer, head and neck cancer and liver cancer.

Harbour BioMed Announces Initiation of First-in-human Study of Next-generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors

Retrieved on:

Monday, November 4, 2019

Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Monoclonal antibodies, Clinical medicine, Medicine, Drugs, Ipilimumab, Tremelimumab, Heavy Chain Only Antibodies (HCAb), Harbour BioMed

Harbour BioMed (HBM) today announced the start of the first clinical trial of its next-generation fully human anti-CTLA-4 antibody (HBM4003) for the treatment of patients with advanced solid tumors.

Key Points:

Harbour BioMed (HBM) today announced the start of the first clinical trial of its next-generation fully human anti-CTLA-4 antibody (HBM4003) for the treatment of patients with advanced solid tumors.
This trial is the first with a fully human antibody based on heavy chain only antibody technology (HCAb).
The trial is designed to assess the safety, pharmacokinetic profile and preliminary anti-tumor activity of HBM4003 in patients with advanced solid tumors.
This trial provides the first opportunity to evaluate how this promising compound will perform in the treatment of solid tumors.

Global Immune Checkpoint Inhibitors Market Outlook 2022: NSCLC & Melanoma Showing Greatest Contributions to the IO Market

Retrieved on:

Tuesday, October 22, 2019

Immune system, Medicine, Organ systems, Medical specialties, Cancer treatments, Checkpoint inhibitor, PD-L1, Immune checkpoint, Programmed cell death protein 1, CTLA-4, PD-1 and PD-L1 inhibitors, Tremelimumab

DUBLIN, Oct. 21, 2019 /PRNewswire/ -- The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Oct. 21, 2019 /PRNewswire/ -- The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering.
The report provides a detailed analysis of the global immune checkpoint inhibitors market.
The global immune checkpoint inhibitors market has been segmented on the basis of type of product into PD-1, PD-L1, and CTLA-4.
On the basis of type of cancer, the immune checkpoint inhibitors market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immune checkpoint inhibitors market.